- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07633366
BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics (BALance)
Check the BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics Profiling and Radiomics
Acute respiratory distress syndrome (ARDS) is a major contributor to ICU mortality and is characterised by hypoxaemia and pulmonary oedema. Pathomechanisms include barrier breakdown, immunopathology, haemostatic derailment and dysbiosis; however, the actual sequence of events and how they cumulatively lead to lung failure remains unclear. Although ARDS is frequently triggered by pneumonia, it can also occur as a result of trauma, aspiration or non-pulmonary causes. Importantly, ARDS is highly heterogeneous; growing evidence points to aetiology-specific pathomechanisms - a circumstance that explains why attempts to develop specific drugs or timely diagnostic markers have so far failed.
A comprehensive analysis of key microenvironmental and haemostasis-related parameters of the lung, combined with multidimensional quantitative image features derived from chest CT scans (radiomics), will enable us to i) identify ARDS phenotypes with different biological characteristics and ii) generate new hypotheses regarding aetiology- or subgroup-specific mechanisms, molecular markers and therapeutic options.
Our approach is based on ICU management of our patients guided by bronchoalveolar lavage fluid (BALF). Together with previously sampled cases and new samples collected as part of this study, our cohort will consist of patients with i) COVID-19-associated ARDS, ii) ARDS associated with other viral pneumonia, iii) ARDS associated with bacterial pneumonia, and iv) ARDS of non-pulmonary origin. Bacterial and fungal co-infections and superinfections are recorded in all patients and taken into account in the stratification. Patients with pneumonia without ARDS, as well as ventilated patients without underlying lung disease, serve as controls. To characterise the microbial lung microenvironment, the investigators combine data from routine microbiological diagnostics with microbiome sequencing and metabolomics. In addition, the investigators conduct comprehensive and longitudinal immune and haemostatic profiling by regularly analysing immune cells, cytokines and parameters of immune thrombosis in BALF and blood. Multi-omics integration then identifies phenotypic subgroups by merging all multimodal datasets - including radiomics. Selected samples from identified clusters are then further characterised using single-cell sequencing to uncover specific features/markers and pathomechanisms of the respective ARDS subtypes.
Although it is clear that the pathogenesis of ARDS is multifactorial, comprehensive studies that integrate all relevant parameters are rare. Radiomics is increasingly recognised as a powerful tool for capturing the clinical status of ARDS in detail; however, to date, this imaging data has not been systematically linked to other omics readouts. The investigators aim to bridging this gap by conducting a thorough investigation across various ARDS aetiologies in the present study, incorporating all identifiable key factors.
Our interdisciplinary team comprises basic immunologists, infectious disease and computational biologists, as well as clinicians with expertise in ARDS, infectious diseases, immunothrombosis and radiology.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: Oliver Robak, Prof. PD Dr.
- Telefonnummer: +43 1 40400 44920
- E-post: oliver.robak@meduniwien.ac.at
Studer Kontakt Backup
- Navn: Riem Gawish, PhD
- Telefonnummer: +43 1 40400 51480
- E-post: riem.gawish@meduniwien.ac.at
Studiesteder
-
-
State of Vienna
-
Vienna, State of Vienna, Østerrike, 1090
- General Hospital of Vienna, Medical University of Vienna
-
Ta kontakt med:
- Oliver Robak, Ap. Prof. Priv.-Doz. Dr.
- Telefonnummer: +43 1 40400 44920
- E-post: oliver.robak@meduniwien.ac.at
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- male and female
- aged 18 years or over
- signed consent form
- depending on the study group: Confirmed ARDS according to the Berlin criteria (see below, Groups B and D) Confirmed severe CAP requiring mechanical ventilation and intensive care (see below, Groups B and C) Ventilated patients without signs of ARDS (see below, Group E)
Exclusion Criteria:
- under 18 years of age
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
COVID-19 ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Andre navn:
|
|
Pneumonia-induced ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Andre navn:
|
|
Severe pneumonia but no ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Andre navn:
|
|
Non-pulmonary origin ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Andre navn:
|
|
No lung pathology
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
ARDS phenotypes
Tidsramme: 4 years
|
The application of multi-omics cluster analysis to reveal any distinct ARDS phenotypes or subgroup-specific characteristics.
|
4 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Lung Microbiome Composition Analysis via 16S rRNA Gene Sequencing of Bronchoalveolar Lavage (BAL) Fluid
Tidsramme: 4 years
|
Differences in the microbial community composition (alpha diversity, beta diversity, and taxonomic abundance at phylum/genus level) of the lower respiratory tract microbiome in intensive care patients with ARDS
|
4 years
|
|
Metabolomic Profile of Bronchoalveolar Lavage Fluid and Plasma
Tidsramme: 4 years
|
Differences in the metabolomic profile (relative concentrations of annotated metabolites and pathway-level scores) in bronchoalveolar lavage (BAL) fluid and plasma between ARDS subgroups (with vs. without bacterial/fungal co-/superinfection).
Metabolomic measurements will be performed using the METAB02, AMINO01, and LIPID01 or other appropriate packages.
Samples will be analyzed via mass spectrometry to quantify a wide range of analytes, including various amino acids, lipids and their subclasses, and metabolites such as pyruvate, lactate, citrate, and succinate.
|
4 years
|
|
Inflammatory Cytokine Profile in Bronchoalveolar Lavage Fluid and Plasma
Tidsramme: 4 years
|
Concentrations of predefined pro- and anti-inflammatory cytokines (e.g., IL-6, IL-8, TNF-α, others according to panel) in BAL fluid and plasma of ARDS patients, and detection of differences between ARDS subgroups (with vs. without bacterial/fungal co-/superinfection) by Multiplex bead-based immunoassay or ELISA panels (e.g., Luminex, electrochemiluminescence).
|
4 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Oliver Robak, Prof. PD Dr., Medical University of Vienna, Department of Medicine 1
- Hovedetterforsker: Riem Gawish, PhD, Medical University of Vienna, Department of Medicine 1
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Luftveisinfeksjoner
- Infeksjoner
- Orthomyxoviridae-infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Sykdommer i luftveiene
- Lungesykdommer
- Lungebetennelse, viral
- Coronavirus-infeksjoner
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- Lungeskade
- Covid-19
- Influensa, menneske
- Lungebetennelse
- Akutt lungeskade
- Saminfeksjon
- Undersøkelsesteknikker
- Terapeutikk
- Paracentesis
- Prøvehåndtering
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Punkteringer
- Kirurgiske prosedyrer, operativ
- Blodprøveinnsamling
- Cordocentesis
Andre studie-ID-numre
- 2405/2025
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på ARDS (Acute Respiratory Distress Syndrome)
-
Ramos Mejía HospitalUniversidad de la RepublicaHar ikke rekruttert ennåRespiratory Distress Syndrome (RDS)
-
HTIC, IncRekrutteringARDS (Acute Respiratory Distress Syndrome)Forente stater
-
Vastra Gotaland RegionGöteborg UniversityHar ikke rekruttert ennåRespiratorisk distress syndrom hos premature spedbarn | Respiratory Distress Syndrome hos nyfødte | Respiratory Distress Syndrome (og [Hyaline Membrane Disease]) | Respiratory Distress Syndrome (RDS) | Respiratorisk nødsyndrom (neonatal)
-
Hospital Dr. Franco Ravera ZuninoHar ikke rekruttert ennåARDS (Acute Respiratory Distress Syndrome)
-
Wolfson Medical CenterUkjent
-
Christiana Care Health ServicesRekrutteringPreTerm nyfødt | Respiratory Distress Syndrome (RDS)Forente stater
-
Xingwang ZhuHunan Provincial People's Hospital; First People's Hospital of Chenzhou; Kunming... og andre samarbeidspartnereHar ikke rekruttert ennåBronkopulmonal dysplasi (BPD) | Respiratory Distress Syndrome (og [Hyaline Membrane Disease])
-
University of CalgaryHar ikke rekruttert ennåARDS (Acute Respiratory Distress Syndrome)
-
Ain Shams UniversityPåmelding etter invitasjonARDS (Acute Respiratory Distress Syndrome)Egypt
-
Ain Shams UniversityFullført
Kliniske studier på sampling blood
-
Human Cell DesignHar ikke rekruttert ennåAmyotrofisk lateral sklerose (ALS)
-
University Hospital, Strasbourg, FranceHar ikke rekruttert ennåSpredt intravaskulær koagulasjon assosiert med septisk sjokkFrankrike
-
University of Maryland, BaltimoreFullført
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)Fullført
-
Ohio State UniversityFullført
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Fullført
-
Hygeia Touch Inc.FullførtInfeksjon av humant papillomavirus | Vaginal utflod | SelvprøvetakingTaiwan
-
University Hospital, Strasbourg, FranceHar ikke rekruttert ennåECMO | Mplementation av en veno-venøs VV eller veno-arteriell VA | IntensivbehandlingFrankrike
-
Case Western Reserve UniversityJohns Hopkins University; Mayo Clinic; University of Pennsylvania; Washington... og andre samarbeidspartnereRekrutteringBarretts spiserør | Neoplasma i spiserøretForente stater
-
H. Lee Moffitt Cancer Center and Research InstituteAmerican Cancer Society, Inc.AvsluttetBukspyttkjertelsvulsterForente stater